Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SALT LAKE CITY, May 05, 2017 -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, announced today that its shares of common stock will be quoted under the symbol “GBSN” beginning today, May 5, 2017. The common stock was previously quoted under the temporary symbol “GBSND” on the OTCQB market as a result of the reverse stock split of its issued and outstanding shares of common stock that became effective on April 10, 2017.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses, and significantly limiting the spread of infectious disease. More information can be found on the Company’s website at www.gbscience.com.
Forward-Looking Statements
This press release may include forward-looking statements which involve risks and uncertainties, and which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Company Contact: Betsy Hartman, Great Basin Scientific 385.215.3372 [email protected]
